Compare Harley-Davidson Inc (HOG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs GeneDx Holdings Corp — how do they compare? Harley-Davidson Inc trades at $26.9 (market cap $2.78B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Harley-Davidson Inc is the larger of the two by market cap, and Harley-Davidson Inc pays a 2.8% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and GeneDx Holdings Corp for 19 Days on average.
| HOG | WGS | |
|---|---|---|
Market Cap | $2.78B | $2.02B |
Volume | 2,966,389 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $167.51 |
52-Week Low | $17.19 | $34.51 |
Typical Hold Time | 92 Days | 19 Days |
Enterprise Value | $3.20B | $2.05B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.90, down 0.19% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings beat ($0.75 vs $0.645 expected) but missed Q1 expectations. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 14.86 and P/S of 0.72. Recent news highlights tariff exposure and a data breach investigation.
The stock offers value with reasonable multiples but faces revenue headwinds and operational challenges. Analyst consensus is cautious with 61% hold ratings and $28.50 price target suggesting limited upside. Key risks include declining motorcycle demand, tariff sensitivity, and competitive pressures in the evolving auto industry.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
